Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study

Table 1 Clinical characteristics of the patients at baseline

Baseline clinical characteristic	Patient nr. 150
Age (years)—mean ± SD	64.3 ± 10.4
Sex (male)—no. (%)	108 (72.0)
Race (Caucasian)—no. (%)	140 (93.3)
Body-mass index (kg/m²)—mean ± SD; no.	29.5 ± 5.1; 148^a
Risk factors—no. (%)
Diabetes mellitus type 1	10 (6.7)
Diabetes mellitus type 2	140 (93.3)
Insulin-dependent diabetes mellitus	47 (31.3)
Diabetes mellitus treated with oral antidiabetic	117 (78.0)
HbA1c (mmol/mol)—mean ± SD; no.	55.5 ± 11.5; 42^a
Arterial hypertension	104 (69.3)
Hypercholesterolemia	100 (66.7)
Family history of cardiovascular disease	59 (39.3)
Current smoker	35 (23.3)
Medical history—no. (%)
Previous ACS	41 (27.3)
Previous PCI	37 (24.7)
Previous CABG	8 (5.3)
Previous CVA or TIA	10 (8.7)
Severe chronic renal failure^b	4 (2.7)
Chronic pulmonary obstructive disease^c	11 (7.3)
Clinical presentation—no. (%)
Acute coronary syndrome	73 (48.7)
ST-segment elevation myocardial infarction	18 (12.0)
Non-ST-segment elevation myocardial infarction	29 (19.3)
Unstable angina pectoris	26 (17.3)
Non-acute coronary syndrome	77 (51.3)
Stable angina pectoris	59 (39.3)
Silent ischemia	8 (5.3)
Other	10 (6.7)

Plus–minus values are means ± standard and the curved numbers ^a represent the known total of which the variable was calculated. ^b Renal insufficiency was defined as estimated glomerular filtration rate of less than 30 ml per minute per 1.73 m² of body surface area (GFR < 30 ml/min/1.73 m²). ^c Chronic pulmonary obstructive disease was defined as ≥ Gold class II
ACS acute coronary syndrome, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, CVA cerebrovascular accident, TIA transient ischemic attack